ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.890
+0.010 (0.53%)
Aug 1, 2025, 4:00 PM - Market closed
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | David Parkinson |
Contact Details
Address: 999 West Broadway, Suite 720 Vancouver, BC V5Z 1K5 Canada | |
| Phone | 778 331 0962 |
| Website | essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer and Director |
| David S. Wood C.M.A., C.P.A., CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Nkengyal Barber | Executive |
| Steve Pondell | Executive |
| Terry Schuenemeyer | Executive |
| Dr. Roger Ulrich Ph.D. | Consultant |
| Dr. Jim Bristol | Consultant |
| Kim Hewitt | Consultant |
| Dr. Stephen Plymate M.D. | Consultant |
| Kally Singh | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 30, 2025 | SCHEDULE 13G | Filing |
| Jul 30, 2025 | PREM14A | Filing |
| Jul 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 23, 2025 | 8-K | Current Report |
| Jul 21, 2025 | SCHEDULE 13D/A | Filing |
| Jul 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 14, 2025 | 8-K | Current Report |